NO20006039L - Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin - Google Patents

Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin

Info

Publication number
NO20006039L
NO20006039L NO20006039A NO20006039A NO20006039L NO 20006039 L NO20006039 L NO 20006039L NO 20006039 A NO20006039 A NO 20006039A NO 20006039 A NO20006039 A NO 20006039A NO 20006039 L NO20006039 L NO 20006039L
Authority
NO
Norway
Prior art keywords
carboxyamino
tetrahydroquinoline
substituted
preparation
Prior art date
Application number
NO20006039A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006039D0 (no
Inventor
David Burns Damon
Robert Wayne Dugger
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20006039D0 publication Critical patent/NO20006039D0/no
Publication of NO20006039L publication Critical patent/NO20006039L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20006039A 1999-11-30 2000-11-29 Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin NO20006039L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (2)

Publication Number Publication Date
NO20006039D0 NO20006039D0 (no) 2000-11-29
NO20006039L true NO20006039L (no) 2001-05-31

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006039A NO20006039L (no) 1999-11-30 2000-11-29 Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin

Country Status (44)

Country Link
US (1) US6313142B1 (cg-RX-API-DMAC7.html)
EP (1) EP1125929B1 (cg-RX-API-DMAC7.html)
JP (1) JP3579345B2 (cg-RX-API-DMAC7.html)
KR (1) KR100408177B1 (cg-RX-API-DMAC7.html)
CN (1) CN1173953C (cg-RX-API-DMAC7.html)
AP (1) AP2000002011A0 (cg-RX-API-DMAC7.html)
AR (1) AR029775A1 (cg-RX-API-DMAC7.html)
AT (1) ATE315028T1 (cg-RX-API-DMAC7.html)
AU (1) AU784694B2 (cg-RX-API-DMAC7.html)
BG (1) BG105009A (cg-RX-API-DMAC7.html)
BR (1) BR0005636A (cg-RX-API-DMAC7.html)
CA (1) CA2327029C (cg-RX-API-DMAC7.html)
CO (1) CO5261552A1 (cg-RX-API-DMAC7.html)
CY (1) CY1104989T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20004407A3 (cg-RX-API-DMAC7.html)
DE (1) DE60025317T2 (cg-RX-API-DMAC7.html)
DK (1) DK1125929T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ3079A1 (cg-RX-API-DMAC7.html)
EA (1) EA003668B1 (cg-RX-API-DMAC7.html)
EE (1) EE200000659A (cg-RX-API-DMAC7.html)
ES (1) ES2254109T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20022798B (cg-RX-API-DMAC7.html)
GT (1) GT200000190A (cg-RX-API-DMAC7.html)
HN (1) HN2000000203A (cg-RX-API-DMAC7.html)
HR (1) HRP20000804A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0004747A3 (cg-RX-API-DMAC7.html)
ID (1) ID28489A (cg-RX-API-DMAC7.html)
IL (1) IL139849A (cg-RX-API-DMAC7.html)
IS (1) IS5715A (cg-RX-API-DMAC7.html)
MA (1) MA25223A1 (cg-RX-API-DMAC7.html)
NO (1) NO20006039L (cg-RX-API-DMAC7.html)
NZ (1) NZ508509A (cg-RX-API-DMAC7.html)
OA (1) OA11494A (cg-RX-API-DMAC7.html)
PA (1) PA8503801A1 (cg-RX-API-DMAC7.html)
PE (1) PE20010913A1 (cg-RX-API-DMAC7.html)
PL (1) PL344208A1 (cg-RX-API-DMAC7.html)
SG (1) SG102603A1 (cg-RX-API-DMAC7.html)
SK (1) SK17792000A3 (cg-RX-API-DMAC7.html)
TN (1) TNSN00230A1 (cg-RX-API-DMAC7.html)
TW (1) TW591016B (cg-RX-API-DMAC7.html)
UA (1) UA65615C2 (cg-RX-API-DMAC7.html)
UY (1) UY26451A1 (cg-RX-API-DMAC7.html)
YU (1) YU71500A (cg-RX-API-DMAC7.html)
ZA (1) ZA200006947B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
US7202247B2 (en) 2001-12-19 2007-04-10 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2003053368A2 (en) * 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
EP1492880B1 (en) * 2002-04-11 2008-10-08 Roar Holding LLC Ex vivo method for determination of cetp activity and efficacy of heart disease treatment
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05003456A (es) * 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) * 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
US20040181075A1 (en) * 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
BR0317521A (pt) 2002-12-20 2005-11-16 Pfizer Prod Inc Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa
JP2006523218A (ja) * 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
PT1603553E (pt) * 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
CA2519458A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合
SI1670768T1 (sl) * 2003-10-08 2010-01-29 Lilly Co Eli Spojine in metode za zdravljenje dislipidemije
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
CA2598133A1 (en) * 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸
EP4551567A1 (en) 2022-07-05 2025-05-14 NewAmsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (cg-RX-API-DMAC7.html) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
CN1173953C (zh) 2004-11-03
GT200000190A (es) 2002-04-27
JP2001163859A (ja) 2001-06-19
PL344208A1 (en) 2001-06-04
HK1038007A1 (en) 2002-03-01
SG102603A1 (en) 2004-03-26
DE60025317T2 (de) 2006-08-03
AP2000002011A0 (en) 2000-12-31
HU0004747D0 (cg-RX-API-DMAC7.html) 2001-02-28
UA65615C2 (uk) 2004-04-15
PE20010913A1 (es) 2001-09-10
EE200000659A (et) 2001-08-15
PA8503801A1 (es) 2002-07-30
ES2254109T3 (es) 2006-06-16
HN2000000203A (es) 2001-06-13
CA2327029C (en) 2005-08-09
KR20010052012A (ko) 2001-06-25
CY1104989T1 (el) 2010-03-03
US6313142B1 (en) 2001-11-06
AR029775A1 (es) 2003-07-16
HRP20000804A2 (en) 2001-06-30
CZ20004407A3 (cs) 2002-06-12
OA11494A (en) 2004-05-07
IL139849A0 (en) 2002-02-10
YU71500A (sh) 2003-02-28
TW591016B (en) 2004-06-11
KR100408177B1 (ko) 2003-12-01
EA200001129A2 (ru) 2001-06-25
CO5261552A1 (es) 2003-03-31
UY26451A1 (es) 2001-06-29
ZA200006947B (en) 2002-05-27
DK1125929T3 (da) 2006-04-03
TNSN00230A1 (fr) 2005-11-10
EA200001129A3 (ru) 2001-10-22
DZ3079A1 (fr) 2004-10-24
CA2327029A1 (en) 2001-05-30
ATE315028T1 (de) 2006-02-15
SK17792000A3 (sk) 2002-10-08
AU7178900A (en) 2001-05-31
MA25223A1 (fr) 2001-07-02
EP1125929A1 (en) 2001-08-22
NO20006039D0 (no) 2000-11-29
BR0005636A (pt) 2001-07-17
EA003668B1 (ru) 2003-08-28
DE60025317D1 (de) 2006-03-30
BG105009A (en) 2001-11-30
NZ508509A (en) 2001-06-29
HUP0004747A3 (en) 2002-12-28
GEP20022798B (en) 2002-09-25
IS5715A (is) 2001-05-31
CN1302800A (zh) 2001-07-11
EP1125929B1 (en) 2006-01-04
JP3579345B2 (ja) 2004-10-20
HUP0004747A2 (hu) 2001-10-28
ID28489A (id) 2001-05-31
IL139849A (en) 2006-10-31
AU784694B2 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
NO20006039L (no) Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin
NO20015017L (no) Fremgangsmate for fremstilling av citalopram
NO20010318D0 (no) Fremgangsmåte for fremstilling av Citalopram
NO20010319D0 (no) Fremgangsmåte for fremstilling av Citalopram
ID28601A (id) Proses penyiapan senyawa-senyawa 1,4-dihidropiridin
NO20003454D0 (no) FremgangsmÕte for fremstilling av (-)cis-3-hydroksy-1-metyl-4-
NO20013407D0 (no) Fremgangsmåte for fremstilling av kinolinkarbaldehyd
NO20000456D0 (no) Fremgangsmåte for fremstilling av 1,2-dikloretan
NO20020059L (no) Fremgangsmåte for fremstilling av dibenzotiazepinderivater
NO20000965D0 (no) Fremgangsmåte for fremstilling av veksthormon-utskillende forbindelser
NO20021727L (no) Fremgangsmåte for fremstilling av 3,4-metylen-dioksy- mandelisk syre
NO20013995L (no) Fremgangsmåte for fremstilling av L-sorbose
HUP0300703A3 (en) Process for the preparation of quinoline derivatives
NO20014383L (no) Fremgangsmåte for fremstilling av syklo-(Asp-DPhe-NMeVal-Arg- Gly)
NO20011652D0 (no) Fremgangsmåte for fremstilling av 1,5-diaryl-3-substituerte pyrazoler
NO20022956L (no) Fremgangsmate for fremstilling av nitroguanidin
NO20012811D0 (no) Fremgangsmåte for fremstilling av p-klorfenyl-propanol- derivat
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20023702D0 (no) Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
NO20013044D0 (no) Fremgangsmåte for fremstilling av NG-substituerte deaza- adenosinderivater
NO20005818L (no) Forbedret fremgangsmåte for fremstilling av farmasöytisk verdifulle norbenzomorfan-derivater
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
NO20020670L (no) Fremgangsmåte for fremstilling av kinolin-5,8-dioner
NO20005743D0 (no) Fremgangsmåte til fremstilling av 4,5-epoksymorfinan-6- oksyglukoronider
NO20002558D0 (no) FremgangsmÕte for fremstilling av findisperse eksplosivstoffer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application